{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:33:31Z","timestamp":1791228811180,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":2261,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2013.07.008","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T13:52:44Z","timestamp":1380289964000},"page":"S44-S47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S2","title":["Obesity and endocrine therapy: Host factors and breast cancer outcome"],"prefix":"10.1016","volume":"22","author":[{"given":"Pamela J.","family":"Goodwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.07.008_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","article-title":"Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis","volume":"123","author":"Protani","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.07.008_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","article-title":"Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis","volume":"134","author":"Niraula","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.07.008_bib3","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1002\/cncr.27527","article-title":"Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer","volume":"118","author":"Sparano","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2013.07.008_bib4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nrc3174","article-title":"Molecular mechanisms of cancer development in obesity","volume":"11","author":"Khandekar","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2013.07.008_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsbmb.2006.09.040","article-title":"Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels","volume":"104","author":"Geisler","year":"2007","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"1 Suppl.","key":"10.1016\/j.breast.2013.07.008_bib6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/ajcn\/45.1.290","article-title":"Effect of aging and obesity on aromatase activity of human adipose cells","volume":"45","author":"Simpson","year":"1987","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.breast.2013.07.008_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1940-6207.CAPR-11-0110","article-title":"Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer","volume":"4","author":"Morris","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.breast.2013.07.008_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2002.20.1.42","article-title":"Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study","volume":"20","author":"Goodwin","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10911-008-9098-0","article-title":"Crosstalk between IGF1R and estrogen receptor signaling in breast cancer","volume":"13","author":"Fagan","year":"2008","journal-title":"J\u00a0Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.breast.2013.07.008_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1158\/1055-9965.EPI-12-0310","article-title":"Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer","volume":"21","author":"Hvidtfeldt","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.breast.2013.07.008_bib11","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/oxfordjournals.aje.a115234","article-title":"The epidemiology of serum sex hormones in postmenopausal women","volume":"129","author":"Cauley","year":"1989","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.breast.2013.07.008_bib12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1055-9965.EPI-07-0761","article-title":"Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer","volume":"17","author":"Rock","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.breast.2013.07.008_bib13","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1158\/1078-0432.CCR-07-5221","article-title":"Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels","volume":"14","author":"Geisler","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2013.07.008_bib14","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2012.42.0273","article-title":"Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer","volume":"30","author":"Folkerd","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-012-2278-z","article-title":"Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels","volume":"136","author":"Diorio","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.07.008_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/clpt.2011.174","article-title":"Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age","volume":"90","author":"Desta","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.breast.2013.07.008_bib17","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib18","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","article-title":"Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial","volume":"28","author":"Sestak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib19","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib20","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","article-title":"Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial","volume":"30","author":"Ewertz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"24 Suppl.","key":"10.1016\/j.breast.2013.07.008_bib21","article-title":"The impact of body mass index on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer patients: exploratory analysis from the TEAM study","volume":"70","author":"Seynaeve","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.07.008_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib23","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2013.07.008_bib24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.bjc.6601557","article-title":"Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer","volume":"90","author":"Forward","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2013.07.008_bib25","article-title":"The efficacy of anastrozole is not dependent upon body mass index in postmenopausal women with advanced breast cancer","volume":"21","author":"Michaud","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib26","article-title":"Body mass index as predictive parameter for response and time to progression in advanced breast cancer patients treated with letrozole or megestrol acetate","volume":"19","author":"Schmid","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2013.07.008_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.breast.2011.07.015","article-title":"Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer","volume":"21","author":"Takada","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.breast.2013.07.008_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2013.07.008_bib29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.07.008_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ctrv.2007.11.001","article-title":"Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review","volume":"34","author":"Eisen","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2013.07.008_bib31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1470-2045(08)70182-7","article-title":"Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis","volume":"9","author":"Sestak","year":"2008","journal-title":"Lancet Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613001434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613001434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:30:05Z","timestamp":1760776205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613001434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":31,"alternative-id":["S0960977613001434"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.008","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity and endocrine therapy: Host factors and breast cancer outcome","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}